Sarim Mir, MD
Neurology · Hagerstown, MDNPI 1497793087
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $2,733 of the $4,266 with a category attached, or 64.1%. Novartis accounts for 71.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $3,626 and has fallen 99.6% since, to $16 in 2025.
Across 72 payments — averaging $59.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- AstraZeneca$385
- Supernus Pharmaceuticals, Inc.$206
- Lilly USA, LLC$103
- AbbVie$73
- UCB, Inc.$67
- plus $400 from 12 others
Across 26 payments — averaging $9370.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$111K
- Novartis$64K
- Avanir Pharmaceuticals, Inc.$35K
- Amgen$21K
- Pfizer$8K
- H. Lundbeck A S$6K
What the payments were for
- Food & beverage$1,19628%
- Education$3378%
- Gifts$2,73364%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $3,031 |
| AstraZeneca | 9 | $385 |
| Supernus Pharmaceuticals, Inc. | 11 | $206 |
| Lilly USA, LLC | 6 | $103 |
| AbbVie(2 entities) | 5 | $73 |
| UCB, Inc. | 4 | $67 |
| Tanabe Pharma America, Inc. | 2 | $65 |
| Livanova USA, Inc. | 2 | $47 |
| Sunovion Pharmaceuticals Inc. | 5 | $42 |
| Amneal Pharmaceuticals LLC | 3 | $41 |
| Amgen | 2 | $41 |
| Genentech USA, Inc. | 3 | $40 |
| Mallinckrodt Enterprises LLC | 1 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Biogen | 1 | $24 |
| Life Molecular Imaging Ltd | 1 | $16 |
| Promius Pharma LLC | 1 | $15 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,266 in reported general payments places this provider in the 60th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 14 | $116,669 |
| UbrelvyUbrogepant | 53 | $73,718 |
| BotoxOnabotulinumtoxina | 16 | $18,023 |
| Emgality PenGalcanezumab-Gnlm | 23 | $15,522 |
| Nurtec OdtRimegepant Sulfate | 14 | $15,087 |
| Levetiracetam | 68 | $3,114 |
| Memantine Hcl | 39 | $1,659 |
| Divalproex Sodium | 12 | $1,400 |
| Gabapentin | 117 | $1,295 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 38 | $930 |
| Duloxetine Hcl | 44 | $744 |
| Donepezil Hcl | 57 | $657 |
| Pregabalin | 35 | $476 |
| Topiramate | 51 | $350 |
| Sumatriptan Succinate | 15 | $235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $24 | $116,66914 claims |
| AbbVieUbrelvy, Botox | $73 | $91,74069 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 442 neurology providers in Maryland.
Other neurology in Hagerstown
- Daniel BeckerLutherville$1.6M
- Sangjin OhGlen Burnie$1.5M
- Pavel KleinBethesda$709K
- Ruwani GunawardaneFulton$479K
- Michael PolydefkisBaltimore$371K
- David CornblathLutherville$345K
- Shiv SaidhaBaltimore$298K
- Santiago Mazuera MesiaBaltimore$258K
- Bruce RabinLutherville$228K
- Thomas CrawfordBaltimore$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.